Mather Group
JAZZ icon

Mather Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Mather Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.7K Buy
68
+46
+209% +$11.4K ﹤0.01% 1507
2026
Q2 		$5.3K Hold
22
– – ﹤0.01% 1610
2026
Q1 		$4.16K Buy
+22
New +$3.84K ﹤0.01% 1602
2025
Q4 		– Sell
-22
Closed -$2.9K – 1162
2025
Q3 		$2.9K Buy
+22
New +$2.64K ﹤0.01% 1489
2025
Q2 		– Sell
-63
Closed -$7.82K – 1182
2025
Q1 		$7.82K Hold
63
– – ﹤0.01% 1309
2024
Q4 		$7.76K Buy
63
+49
+350% +$5.78K ﹤0.01% 1298
2024
Q3 		$1.56K Sell
14
-120
-90% -$13.2K ﹤0.01% 1517
2024
Q2 		$16.1K Buy
134
+41
+44% +$4.51K ﹤0.01% 1314
2024
Q1 		$11.4K Buy
+93
New +$11.4K ﹤0.01% 1165

Other funds holding JAZZ

AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
Argent Capital Management
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Mather Group's JAZZ Position: Q3 2026 in Review

Mather Group increased its Jazz Pharmaceuticals (JAZZ) stake by 209% in Q3 2026, buying an estimated $11.4K and bringing the position to 68 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

Mather Group first reported a position in JAZZ in Q1 2024 and has held it in 9 quarters since. The position peaked at $16.1K in Q2 2024. 120 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Mather Group held 68 shares of Jazz Pharmaceuticals worth $15.7K as of Q3 2026.
  • Mather Group bought 46 Jazz Pharmaceuticals shares in Q3 2026, an estimated $11.4K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1507 holding.
  • Mather Group first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Mather Group's Jazz Pharmaceuticals position peaked at $16.1K in Q2 2024.
  • 120 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.